Drug Profile
Research programme: serotonin 4 receptor agonists - Suven Life Sciences
Alternative Names: SUVN-D1003019Latest Information Update: 28 May 2022
Price :
$50
*
At a glance
- Originator Suven Life Sciences
- Class Antidementias; Neuroprotectants; Small molecules
- Mechanism of Action Serotonin 4 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Alzheimer's disease; Neurodegenerative disorders
Most Recent Events
- 28 May 2022 No recent reports of development identified for preclinical development in Neurodegenerative-disorders in India (PO)
- 29 Aug 2018 Suven Life Sciences secures product patents for selective 5-HT4 compounds in Neurodegenerative disorders in Eurasia and China
- 07 Aug 2018 Suven Life Sciences secures product patents for selective 5-HT4 and H3 compounds in Mexico and New Zealand